Pharmacological Innovations and Challenges in Cancer-Targeted Therapies
Keywords:
pharmacological innovations, cancer-targeted therapies, oncology treatment, molecular changes, tumor growth, key molecules, tumorigenesis, small molecule inhibitors, monoclonal antibodies, immunotherapies, gene therapies, obtained drug resistance, heterogeneous tumor responses, predictive biomarkers, targeted healing procedures, tumor biology, drug development strategies, resistance mechanisms, precision medicine, healthcare systems, accessibility, collaborative initiatives, cancer treatmentAbstract
Cancer-centered therapies have revolutionized the panorama of oncology treatment, impartingpromising challenges to cope with unique molecular changes driving tumor growth and progression.Over the past few decades, big strides have been made in pharmacological innovations towarddesigning drugs that selectively goal key molecules worried in tumorigenesis, such as oncogenes,increase factors, and signaling pathways. The development of small molecule inhibitors, monoclonalantibodies, immunotherapies, and gene therapies has supplied tailor-made alternatives for variouscancers kinds, enhancing treatment efficacy while minimizing systemic toxicity. However, despite theseimprovements, demanding situations persist, including obtained drug resistance, heterogeneous tumorresponses, and the want for predictive biomarkers to guide patient selection. Additionally, the high valueof targeted healing procedures and the complexity of tumor biology obstacles to considerableaccessibility. Addressing these challenges calls for concerted efforts in refining drug improvementstrategies, elucidating resistance mechanisms, advancing precision medicinal drug strategies, andoptimizing healthcare structures for equitable admission to revolutionary cancer treatments. Theongoing research endeavors and collaborative initiatives geared toward overcoming those hurdlesmaintain promise for similarly enhancing the effectiveness and accessibility of centered healingprocedures within the combat in opposition to cancer.References
Beg, S., & Rahman, M. (2022). Nanomedicine for Cancer: Targeted Therapy, Vaccination, Pharmacokinetics, and Challenges. Current Drug Metabolism, 23(8), 586–586. https://doi.org/10.2174/138920022308221111164626
Crisci, S., Amitrano, F., Saggese, M., Muto, T., Sarno, S., Mele, S., Vitale, P., Ronga, G., Berretta, M., & Di Francia, R. (2019). Overview of Current Targeted Anti-Cancer Drugs for Therapy in Onco-Hematology. Medicina, 55(8). https://doi.org/10.3390/medicina55080414
Fountzilas, E., & Tsimberidou, A. M. (2018). Overview of precision oncology trials: challenges and opportunities. Expert Review of Clinical Pharmacology, 11(8), 797–804. https://doi.org/10.1080/17512433.2018.1504677
Fu, C., Yu, L., Miao, Y., Liu, X., Yu, Z., & Wei, M. (2023). Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope? Acta Pharmaceutica Sinica B, 13(2), 498–516. https://doi.org/10.1016/j.apsb.2022.07.020
Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022). Antibody-drug conjugate: the "biological missile" for targeted cancer therapy. Signal Transduction and Targeted Therapy, 7(1). https://doi.org/10.1038/s41392-022-00947-7
He, S., Du, Y., Tao, H., & Duan, H. (2023). Advances in aptamer-mediated targeted delivery system for cancer treatment. International Journal of Biological Macromolecules, 238, 124173. https://doi.org/10.1016/j.ijbiomac.2023.124173
Hsu, J. C., Jia Yu Lin, Lin, P., & Yang Cheng Lee. (2019). Comprehensive value assessment of drugs using a multi-criteria decision analysis: An example of targeted therapies for metastatic colorectal cancer treatment. PLOS ONE, 14(12), e0225938–e0225938. https://doi.org/10.1371/journal.pone.0225938
Kumar, A., & Kumar, A. (2023). Chitosan-Based Drug Conjugated Nanocomposites: Advances and Innovation in Cancer Therapy. Regenerative Engineering and Translational Medicine. https://doi.org/10.1007/s40883-023-00310-4
Luiza Steffens Reinhardt, Cox, M., Jussânia Gnoatto, Wawruszak, A., Hałasa, M., Pablo Ricardo Arantes, Rowan, N. J., & Dinara Jaqueline Moura. (2021). Polymeric Nanocomposites for Cancer-Targeted Drug Delivery. Advances in Material Research and Technology, 241–270. https://doi.org/10.1007/978-3-030-70266-3_8
Magalhaes, L. G., Ferreira, L. L. G., Andricopulo, A. D., Magalhaes, L. G., Ferreira, L. L. G., & Andricopulo, A. D. (2018). Recent Advances and Perspectives in Cancer Drug Design. Anais Da Academia Brasileira de Ciências, 90(1), 1233–1250. https://doi.org/10.1590/0001-3765201820170823
Mereiter, S., Balmaña, M., Campos, D., Gomes, J., & Reis, C. A. (2019). Glycosylation in the Era of Cancer-Targeted Therapy: Where Are We Heading? Cancer Cell, 36(1), 6–16. https://doi.org/10.1016/j.ccell.2019.06.006
Pereira-Silva, M., Alvarez-Lorenzo, C., Concheiro, A., Santos, A. C., Veiga, F., & Figueiras, A. (2020). Nanomedicine in osteosarcoma therapy: Micelleplexes for delivery of nucleic acids and drugs toward osteosarcoma-targeted therapies. European Journal of Pharmaceutics and Biopharmaceutics, 148, 88–106. https://doi.org/10.1016/j.ejpb.2019.10.013
Su, C., Ren, X., Nie, F., Li, T., Lv, W., Li, H., & Zhang, Y. (2021). Current advances in ultrasound-combined nanobubbles for cancer-targeted therapy: a review of the current status and future perspectives. RSC Advances, 11(21), 12915–12928. https://doi.org/10.1039/d0ra08727k
Subhan, A., & Torchilin, V. P. (2023). Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate. Pharmaceutics, 15(4), 1242–1242. https://doi.org/10.3390/pharmaceutics15041242
Sun, X., Liu, K., Lu, S., He, W., & Du, Z. (2022). Targeted Therapy and Immunotherapy for Heterogeneous Breast Cancer. Cancers, 14(21), 5456. https://doi.org/10.3390/cancers14215456
Tang, L., Li, J., Zhao, Q., Pan, T., Zhong, H., & Wang, W. (2021). Advanced and Innovative Nano-Systems for Anticancer Targeted Drug Delivery. Pharmaceutics, 13(8), 1151. https://doi.org/10.3390/pharmaceutics13081151
Wang, S., Chen, Y., Guo, J., & Huang, Q. (2023). Liposomes for Tumor Targeted Therapy: A Review. International Journal of Molecular Sciences, 24(3), 2643. https://doi.org/10.3390/ijms24032643
Wang, W., Chen, K., Su, Y., Zhang, J., Li, M., & Zhou, J. (2018). Lysosome-Independent Intracellular Drug/Gene Codelivery by Lipoprotein-Derived Nanovector for Synergistic Apoptosis-Inducing Cancer-Targeted Therapy. Biomacromolecules, 19(2), 438–448. https://doi.org/10.1021/acs.biomac.7b01549
Yoon, A-Rum., Hong, J., Jung, B., Ahn, H., Zhang, S. N., & Yun, C. (2023). Oncolytic adenovirus as pancreatic cancer-targeted therapy: Where do we go from here? Cancer Letters, 216456–216456. https://doi.org/10.1016/j.canlet.2023.216456
Zhang, H., Dong, S., Li, Z., Feng, X., Xu, W., Mae, C., Jiang, Y., & Ding, J. (2020). Biointerface engineering nanoplatforms for cancer-targeted drug delivery. Asian Journal of Pharmaceutical Sciences, 15(4), 397–415. https://doi.org/10.1016/j.ajps.2019.11.004
Zhang, M., Hu, S., Liu, L., Dang, P., Liu, Y., Sun, Z., Qiao, B., & Wang, C. (2023). Engineered exosomes from different sources for cancer-targeted therapy. Signal Transduction and Targeted Therapy, 8, 124. https://doi.org/10.1038/s41392-023-01382-y
This work is licensed under a 